In comparison, an annual contrast-enhanced MRI/CT demonstrated superior performance to biannual US in the surveillance of early-stage HCC, and its combination with AFP was not statistically different for MRI (11, 12). The gene discussed is AFP; the disease is hepatocellular carcinoma.